Participant flow

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer · Source last updated 2023-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ramucirumab (10 milligram/kilogram \[mg/kg\]) intravenously (IV) plus docetaxel (75 milligram/square meter \[mg/m²\]) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

   id

   FG000

   title

   Ramucirumab + Docetaxel

2. description

   Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

   id

   FG001

   title

   Placebo + Docetaxel

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         12

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         13

      2. group Id

         FG001

         num Subjects

         14

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         185

      2. group Id

         FG001

         num Subjects

         200

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         2

      type

      Randomized, But Never Treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         263

      2. group Id

         FG001

         num Subjects

         267

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         258

      2. group Id

         FG001

         num Subjects

         265

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         46

      2. group Id

         FG001

         num Subjects

         39

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         217

      2. group Id

         FG001

         num Subjects

         228

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Completers include participants who are confirmed to be alive at study completion.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice